Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Earnings Results, Beats Estimates By $0.04 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) issued its earnings results on Monday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• ALTITUDE-AD Phase II results are expected in November 2026, with primary iADRS results, CDR-SB and other secondary outcomes, safety data, and imaging and fluid biomarker results. Management views the trial as a potential foundation for a registration package and a subsequent single confirmatory Phase III study.
• Management identified approximately 30% slowing on iADRS over 18 months as the efficacy benchmark for advancing sabirnetug, while anticipating low-double-digit ARIA-E rates. The 12-month open-label extension has more than 95% rollover but is expected to generate data into 2027 rather than be included in the initial top-line readout.
• Acumen reported encouraging preclinical results for its enhanced brain delivery program, including up to 40-fold greater frontal-cortex exposure for ACU401 in non-human primates while preserving A-beta oligomer selectivity and a clean hematological profile. The company is advancing ACU301 and ACU401 toward an IND filing expected in mid-2027.
• Acumen ended the quarter with approximately $79 million in cash and marketable securities, which management expects to fund current operations only into early 2027. Third-quarter net loss was $25.4 million, including $21.1 million in R&D expenses, indicating likely future financing needs depending on clinical results and development plans.

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $2.27 on Tuesday. The firm has a 50 day moving average of $2.50 and a 200-day moving average of $2.50. Acumen Pharmaceuticals has a 12-month low of $1.50 and a 12-month high of $3.60. The company has a current ratio of 2.47, a quick ratio of 2.47 and a debt-to-equity ratio of 0.21. The company has a market cap of $164.17 million, a price-to-earnings ratio of -1.39 and a beta of 0.33.

Wall Street Analysts Forecast Growth

ABOS has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday, October 2nd. Citigroup increased their price objective on Acumen Pharmaceuticals from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Wall Street Zen downgraded Acumen Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, October 17th. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, September 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acumen Pharmaceuticals in a research note on Thursday, September 17th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

More Acumen Pharmaceuticals News

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen reported a third-quarter loss of $0.35 per share, narrower than the $0.39 loss analysts expected. The earnings beat helped support the stock’s advance. Acumen Pharmaceuticals beats Q3 estimates
• Positive Sentiment: The company expects to report topline results in November 2026 from ALTITUDE-AD, a Phase 2 trial evaluating sabirnetug (ACU193) in early Alzheimer’s disease. The approaching data readout is the main near-term catalyst discussed on the earnings call. Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Acumen held $78.6 million in cash, cash equivalents and marketable securities at September 30. Management expects this funding to support current clinical and operating activities into early 2027, reducing immediate financing pressure. Acumen Pharmaceuticals third-quarter earnings results
• Neutral Sentiment: The earnings call focused on execution of ALTITUDE-AD and the company’s next-generation Enhanced Brain Delivery program. Acumen is targeting an IND filing for the program’s lead clinical candidate by mid-2027, a longer-term development milestone rather than an immediate revenue driver. Acumen Pharmaceuticals’ Earnings Call Pivots on ALTITUDE-AD
• Negative Sentiment: Acumen remains unprofitable, with analysts expecting a full-year loss of approximately $1.60 per share. The stock’s outlook therefore remains highly dependent on the upcoming ALTITUDE-AD results and the company’s ability to fund development beyond its projected cash runway.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease and other neurodegenerative disorders. The company’s research centers on amyloid beta oligomers, toxic protein assemblies that Acumen believes contribute to the development and progression of Alzheimer’s disease.

Acumen’s lead product candidate is sabirnetug, also known as ACU193, an investigational humanized monoclonal antibody designed to selectively target soluble amyloid beta oligomers.